Sigyn Therapeutics (SIGY) Cash from Investing Activities (2016 - 2022)
Sigyn Therapeutics (SIGY) posted Cash from Investing Activities of -$1.0 for Q3 2022, up 99.99% sequentially from -$9059.0 in Q4 2021, and up 99.99% YoY from -$0.5 in Q3 2021.
Sigyn Therapeutics (SIGY) Cash from Investing Activities (2016 - 2022) Analysis & Trends
Sigyn Therapeutics has reported Cash from Investing Activities for 7 years, with the latest figure at -$1.0 in Q3 2022.
- Quarterly Cash from Investing Activities rose 99.99% year-over-year to -$1.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was -$26394.0 (up 9.81% YoY) and the FY2022 annual result came in at -$860.0, up 97.06% from the prior year.
- Cash from Investing Activities rose to -$1.0 in Q3 2022 per SIGY's latest filing, from -$9059.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $100000.0 in Q1 2019 and troughed at -$17334.0 in Q3 2021.
- A 5-year average of $6331.8 and a median of -$2013.0 in 2018 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2021 and 2022: Cash from Investing Activities sank 121.02% in 2021, then jumped 99.99% in 2022.
- Over 5 years, Cash from Investing Activities stood at -$2013.0 in 2018, then soared by 5067.71% to $100000.0 in 2019, then plunged by 109.5% to -$9500.0 in 2020, then advanced by 4.64% to -$9059.0 in 2021, then soared by 99.99% to -$1.0 in 2022.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$1.0, -$9059.0, and -$17334.0 for Q3 2022, Q4 2021, and Q3 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -1.00 |
| Sep 30, 2022 | -1.00 |
| Dec 31, 2021 | -9,059.00 |
| Dec 31, 2021 | -9,059.00 |
| Sep 30, 2021 | -17,334.00 |
| Sep 30, 2021 | -17,334.00 |
| Mar 31, 2021 | -2,871.00 |
| Mar 31, 2021 | -2,871.00 |
| Sep 30, 2020 | -9,500.00 |
| Sep 30, 2020 | -9,500.00 |
| Mar 31, 2020 | -1,299.00 |
| Mar 31, 2020 | -1,299.00 |
| Mar 31, 2019 | 100,000.00 |
| Mar 31, 2019 | 100,000.00 |
| Dec 31, 2018 | -2,013.00 |
| Dec 31, 2018 | -2,013.00 |
| Sep 30, 2018 | -937.00 |
| Sep 30, 2018 | -937.00 |
| Dec 31, 2017 | -10,740.00 |
| Dec 31, 2017 | -10,740.00 |